RESEARCH OVERVIEW – ANTHRACYCLINES
An Italian study published in 2019 assessed the effectiveness of scalp cooling with DigniCap for patients receiving adjuvant chemotherapy with an anthracycline with or without taxanes.
Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines.
British Journal of Cancer (2019) 121:325-331
Munzone, E, et al.
- The DigniCap System was able to prevent significant hair loss in 43% of breast cancer patients receiving adjuvant chemotherapy.
- The study had a lower than expected dropout rate with only 7% discontinuation. Among the patients that continued, the success rate was 54%.
- None of the patients who participated in the study using DigniCap developed scalp metastases after a mean follow-up of 2.4 years.
Please note that the content of this website is not intended as professional medical or healthcare advice and should not be construed as a substitute for professional healthcare advice, or services from a qualified professional healthcare provider familiar with your unique situation. This content is intended solely as a general product and corporate information.
10925 Estate Lane, Suite 185
Dallas, TX 75238
226 60 Lund, Sweden
+46 46 16 30 90
Corso di Porta Nuova, 46
20121 Milan, Italy